Related Experiment Videos
Pharmacogenetics-based therapeutic recommendations--ready for clinical practice?
Julia Kirchheiner1, Uwe Fuhr, Jürgen Brockmöller
1Department of Pharmacology, University of Cologne, Gleueler Strasse 24, 50931, Köln, Germany. julia.kirchheiner@uk-koeln.de
Nature Reviews. Drug Discovery
|August 2, 2005
Summary
Pharmacogenetics (PGx) offers personalized medicine benefits but requires standardized guidelines for drug development and clinical use. Developing clear recommendations for PGx implementation is crucial for effective individualized therapy and drug dosage.
Area of Science:
- Pharmacogenetics
- Clinical Pharmacology
- Drug Development
Background:
- Pharmacogenetics (PGx) research has advanced, but its application in diagnostics for drug development and clinical practice remains limited.
- Individualized therapy based on PGx data could benefit patients using current medications, yet specific dosage recommendations are lacking.
- Standardization of study designs and data handling is needed for efficient PGx application in drug development and therapy.
Approach:
- This work advocates for the creation of concise guidelines.
- Focuses on the implementation of PGx analyses in both drug development and clinical therapy.
Key Points:
- Limited translation of pharmacogenetic research into clinical diagnostics and drug development.
- Need for actionable recommendations, especially regarding dosage, for individualized therapy.
- Requirement for standardized study designs and data management in pharmacogenetics.
Conclusions:
- Concise guidelines are essential for implementing pharmacogenetics (PGx) analyses.
- Standardization will facilitate the efficient application of PGx in drug development and clinical practice.
- Bridging the gap between pharmacogenetic research and its practical application is critical for personalized medicine.